ICICI Lombard Q1 FY27 Results Analysis: PAT Down 46%, Combined Ratio Worsens to 107.2% (ICICIGI)
ICICI Lombard General Insurance Company Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 6,813.71 Cr (+12.00% YoY) and PAT growth of -46.00% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 16, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 6,813.71 Cr (+12.00% YoY) |
| PAT (Q1) | Rs. 403.17 Cr (-46.00% YoY) |
| EPS (Q1) | Rs. 8.08 (-46.30% YoY) |
| Market cap | Rs. 90,600.76 Cr |
| CMP | Rs. 1,814.60 |
Quarter Snapshot
ICICI Lombard reported a weak Q1 with PAT down 46% YoY and combined ratio worsening to 107.2%, primarily due to a Rs.16,500 Lakh reserve from the Supreme Court ruling on Motor TP claims. While Health Retail emerged as a bright spot with 50.2% premium growth and a swing to profitability, the overall underwriting loss widened sharply, and the near-term outlook hinges on the review petition and potential tariff relief.
Key Investment Insights
Key Positives
- Health Retail premium grew 50.2% YoY and turned to operating profit of Rs.3,388 Lakh from a loss of Rs.8,456 Lakh.
- Net Premium Written grew 17.7% YoY, indicating higher retention.
- Solvency ratio improved to 2.71x from 2.67x at FY26.
- Fair Value Change Account turned positive to Rs.7,220 Lakh from negative Rs.73,548 Lakh, adding Rs.80,768 Lakh to shareholders' funds.
- Crop segment turned to underwriting profit of Rs.521 Lakh from a loss of Rs.413 Lakh.
Risk Factors
- PAT declined 46.0% YoY to Rs.40,317 Lakh, driven by underwriting loss.
- Combined ratio deteriorated 430 bps YoY to 107.2% from 102.9%.
- Underwriting loss widened 115% YoY to Rs.62,988 Lakh.
- Motor underwriting loss widened 131% YoY to Rs.24,521 Lakh, primarily due to Supreme Court judgment claim reserve of Rs.16,500 Lakh.
- Health Group/Corporate underwriting loss exploded 193% YoY to Rs.30,173 Lakh.
- Commission expense grew 32.9% YoY, outpacing premium growth and squeezing margins.
- Total expenses grew 21.2% vs revenue growth of 12.0%, a 920 bps gap indicating margin compression.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.